Advertisement
Screener

Apyx Medical Corp (APYX) Increase (Decrease) in Income Taxes Receivable

Apyx Medical Corp Increase (Decrease) in Income Taxes Receivable

Apyx Medical Corp (APYX) reported Increase (Decrease) in Income Taxes Receivable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2025-03-13

  • Apyx Medical Corp increase (decrease) in income taxes receivable for the quarter ending 2024-12-31 was $0.00.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for the quarter ending 2024-09-30 was $0.00.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for the quarter ending 2024-06-30 was $0.00.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for fiscal 2024 was $0.00.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for fiscal 2023 was -$7.54M.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for fiscal 2022 was -$97.00K.
  • Apyx Medical Corp increase (decrease) in income taxes receivable for fiscal 2021 was -$12.00K, a 100.17% decline from fiscal 2020.
Period endIncrease (Decrease) in Income Taxes Receivable 1 monthIncrease (Decrease) in Income Taxes Receivable 3 monthIncrease (Decrease) in Income Taxes Receivable 6 monthIncrease (Decrease) in Income Taxes Receivable 9 monthIncrease (Decrease) in Income Taxes Receivable 12 month
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
$0.00
derived: sum of 2 quarters · filed 2025-03-13
$0.00
derived: sum of 3 quarters · filed 2025-03-13
$0.00
10-K · filed 2025-03-13
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$0.00
derived: sum of 2 quarters · filed 2024-11-08
$0.00
10-Q · filed 2024-11-08
$0.00
derived: sum of 4 quarters · filed 2025-03-13
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$0.00
10-Q · filed 2024-08-08
$0.00
derived: sum of 3 quarters · filed 2025-03-13
-$7.75M
derived: sum of 4 quarters · filed 2025-03-13
2024-03-31$0.00
10-Q · filed 2024-05-09
$0.00
derived: sum of 2 quarters · filed 2025-03-13
-$7.75M
derived: sum of 3 quarters · filed 2025-03-13
-$7.75M
derived: sum of 4 quarters · filed 2025-03-13
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
-$7.75M
derived: sum of 2 quarters · filed 2025-03-13
-$7.75M
derived: sum of 3 quarters · filed 2025-03-13
-$7.54M
10-K · filed 2025-03-13
2023-09-30-$7.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
-$7.75M
derived: sum of 2 quarters · filed 2024-11-08
-$7.54M
10-Q · filed 2024-11-08
-$7.54M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$207.00K
10-Q · filed 2024-08-08
$207.00K
derived: sum of 3 quarters · filed 2024-08-08
$110.00K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$207.00K
10-Q · filed 2024-05-09
$207.00K
derived: sum of 2 quarters · filed 2024-05-09
$110.00K
derived: sum of 3 quarters · filed 2024-05-09
$110.00K
derived: sum of 4 quarters · filed 2024-05-09
2023-01-31$200.00K
10-K · filed 2024-03-21
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$97.00K
derived: sum of 2 quarters · filed 2024-03-21
-$97.00K
derived: sum of 3 quarters · filed 2024-03-21
-$97.00K
10-K · filed 2024-03-21
2022-09-30-$97.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$97.00K
derived: sum of 2 quarters · filed 2023-11-09
-$97.00K
10-Q · filed 2023-11-09
-$109.00K
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$0.00
10-Q · filed 2023-08-11
-$12.00K
derived: sum of 3 quarters · filed 2023-08-11
-$12.00K
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31$0.00
10-Q · filed 2023-05-11
-$12.00K
derived: sum of 2 quarters · filed 2023-05-11
-$12.00K
derived: sum of 3 quarters · filed 2023-05-11
-$12.00K
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$12.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
-$12.00K
derived: sum of 2 quarters · filed 2023-03-16
-$12.00K
derived: sum of 3 quarters · filed 2023-03-16
-$12.00K
10-K · filed 2023-03-16
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$0.00
10-Q · filed 2022-11-10
$416.00K
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$0.00
10-Q · filed 2021-08-12
$416.00K
derived: sum of 3 quarters · filed 2022-03-17
$1.21M
derived: sum of 4 quarters · filed 2022-03-17
2021-03-31$0.00
10-Q · filed 2021-05-12
$416.00K
derived: sum of 2 quarters · filed 2022-03-17
$1.21M
derived: sum of 3 quarters · filed 2022-03-17
$2.59M
derived: sum of 4 quarters · filed 2022-03-17
2020-12-31$416.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$1.21M
derived: sum of 2 quarters · filed 2022-03-17
$2.59M
derived: sum of 3 quarters · filed 2022-03-17
$7.23M
10-K · filed 2022-03-17
2020-09-30$795.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$2.17M
derived: sum of 2 quarters · filed 2021-11-12
$6.81M
10-Q · filed 2021-11-12
2020-06-30$1.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$6.02M
10-Q · filed 2021-08-12
2020-03-31$4.64M
10-Q · filed 2021-05-12
2019-12-31-$180.00K
10-K · filed 2021-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Microbot Medical Inc. (MBOT)$0.089B-7.97
KORU Medical Systems, Inc. (KRMD)United States$0.151B-106.78
LENSAR, Inc. (LNSR)United States$0.087B2.02
SkinHealth Systems Inc. (SKIN)United States$0.086B-3.17
Pulmonx Corp (LUNG)United States$0.082B-1.16
RenovoRx, Inc. (RNXT)United States$0.076B-3.62
FRACTYL HEALTH, INC. (GUTS)United States$0.075B-1.18
Lucid Diagnostics Inc. (LUCD)United States$0.170B
CVRx, Inc. (CVRX)United States$0.067B-2.62
DarioHealth Corp. (DRIO)$0.066B-1.39